Skip to content

A randomized controlled study on the prevention and relief of radiation enteritis after radiotherapy for prostate cancer using probiotics

A randomized controlled study on the prevention and relief of radiation enteritis after radiotherapy for prostate cancer using probiotics

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500107166
Enrollment
Unknown
Registered
2025-08-05
Start date
2025-08-11
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

Control group:Oral placebo

Sponsors

Peking University First Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1. Patients with pathologically confirmed prostate cancer and planning to undergo radiotherapy; 2. Age 40-85 years old; 3. Those who are expected to survive for more than 12 months; 4. Volunteer to participate in this experiment and sign the informed consent form, and can cooperate with sampling and follow-up.

Exclusion criteria

Exclusion criteria: 1. Those who have used antibiotics, proton pump inhibitors, probiotics, prebiotics and prebiotics and other drugs and preparations that affect intestinal microbes within 4 weeks; 2. Active infection within 12 weeks, including mycobacterial infection, opportunistic infection, etc.; Those who are combined with intestinal perforation, intestinal obstruction, sepsis and other diseases; 3. Chronic infectious diseases that are active: such as chronic hepatitis B, AIDS, or tuberculosis; 4. Patients with recurrent colitis and proctitis (more than 1 time/month), Crohn's disease, ulcerative coloritis, and diarrhea (4 times or more) before radiotherapy; 5. Diagnosis of other malignant tumors within 2 years, tumors are not controlled; 6. Those with serious diseases of other organs; 7. Those with severe allergies; 8. Long-term use of immunosuppressants or concomitant use of immunostimulants after organ transplantation; 9. Those who have participated in any drug clinical trial (as subjects) within 12 weeks before screening and have received drug intervention.

Design outcomes

Primary

MeasureTime frame
Diarrhea grade;

Secondary

MeasureTime frame
The time and frequency of antidiarrheal drug administration;LENT-SOMA score;Complete blood test;Blood biochemistry;Lymphocyte subsets;Intestinal microbiota;oral microbiota;12-plex cytokine panel;antioxidant indicators;

Countries

China

Contacts

Public ContactLi Hongzhen

Peking University First Hospital

hongzhen.li@pkufh.com+86 137 1889 5126

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026